Immunotherapy of cancer in 2012
Year: 2012
Type: review
Abstract: The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology. These principles have been critical in the development of immunotherapy in the laboratory and in the implementation of immunotherapy in the clinic. This improved understanding of immunotherapy, enhanced by increased insights into the mechanism of tumor immune response and its evasion by tumors, now permits manipulation of this interaction and elucidates the therapeutic role of immunity in cancer. Also important, this improved understanding of immunotherapy and the mechanisms underlying immunity in cancer has fueled an expanding array of new therapeutic agents for a variety of cancers. Pegylated interferon-α2b as an adjuvant therapy and ipilimumab as therapy for advanced disease, both of which were approved by the United States Food and Drug Administration for melanoma in March 2011, are 2 prime examples of how an increased understanding of the principles of tumor biology and immunology have been translated successfully from the laboratory to the clinical setting. Principles that guide the development and application of immunotherapy include antibodies, cytokines, vaccines, and cellular therapies. The identification and further elucidation of the role of immunotherapy in different tumor types, and the development of strategies for combining immunotherapy with cytotoxic and molecularly targeted agents for future multimodal therapy for cancer will enable even greater progress and ultimately lead to improved outcomes for patients receiving cancer immunotherapy.
DOI: 10.3322/caac.20132
Institutions: UPMC Hillman Cancer Center, University of Pittsburgh
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,330
Awards: G1055849938, Antigen processing and HLA-peptide complexes in head and neck cancer, Combinatorial targeting of melanoma initiating cells, G1649641201, Eastern Cooperative Oncology Group (Main Institution), Regulation of DC Activity by Memory and Effector CD8+ T Cells, G2417703257, G2452077596, G3162223655, G335493550, Integrating NK and DC into Cancer Therapy, G3670995956, Rational Design of HMW-MAA Peptide Mimics, G424558205, G4592745280, G4730285736, Directing Tumor-specific T cells to Tumors, SPORE in Skin Cancer, G571185835, G5733733469, Optimization of Melanoma Vaccines with T-Helper Epitopes, Polarized DC as Melanoma Vaccine: Phase 1 Evaluation, G6661617200, Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer, G7317943688, TCR Affinity and Therapeutic Efficacy of T Cells, Eastern Cooperative Oncology Group Operations Office, Melanoma Vaccines with Peptides, Protein and Adjuvant, Reversing melanoma-induced T cell dysfunction, Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications, G888658292, Cancer Center Support Grant, G92974733, G964706321
OpenAlex ID: W2001131198